Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 4/20 | 0.59 |
| ▸ | PPARA | Q07869 | 4/20 | 0.59 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | POLA1 | P09884 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | CES2 | O00748 | 4/20 | 0.46 |
| ▸ | CES1 | P23141 | 4/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | TERT | O14746 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | BLM | P54132 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | FABP4 | P15090 | 2/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.44 |
| ▸ | PPARD | Q03181 | 2/20 | 0.44 |
| ▸ | GMNN | O75496 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17782010 | 1.00 | PPARG (0.59) | PPARGPPARATRPA1POLBPOLA1 | |
| SCHEMBL12969168 | 0.93 | PPARG (0.52) | PPARGPPARATRPA1POLBPOLA1 | |
| SCHEMBL5872449 | 0.86 | PPARG (0.64) | PPARGPPARAKDM4EHSD17B10FABP4 | |
| SCHEMBL5872458 | 0.86 | PPARG (0.64) | PPARGPPARAKDM4EHSD17B10FABP4 | |
| SCHEMBL7849545 | 0.84 | PPARG (0.61) | PPARGPPARATRPA1POLBPOLA1 | |
| SCHEMBL12969166 | 0.84 | — | — | |
| SCHEMBL15549003 | 0.83 | PPARG (0.65) | PPARGPPARATRPA1POLBPOLA1 | |
| SCHEMBL6064461 | 0.83 | PPARG (0.70) | PPARGPPARATRPA1POLBPOLA1 | |
| SCHEMBL6064465 | 0.83 | PPARG (0.70) | PPARGPPARATRPA1POLBPOLA1 | |
| SCHEMBL28432886 | 0.83 | PPARG (0.65) | PPARGPPARATRPA1POLBPOLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220057384-A1 | SLEEP MODULATION AGENT | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2022-02-24 | — | — | US | claimed |
| EP-3897599-A1 | SLEEP MODULATION AGENT | Oxford University Innovation Limited (GB) | 2021-10-27 | — | — | EP | claimed |
| WO-2020128481-A1 | SLEEP MODULATION AGENT | OXFORD UNIVERSTITY INNOVATION LIMITED (GB) | 2020-06-25 | — | — | WO | claimed |
| US-12527822-B2 | Methods, compositions, and kits for improving pancreatic beta cell viability and treating diseases or conditions related to beta cell destruction | CITY OF HOPE (US) | 2026-01-20 | — | — | US | disclosed |
| US-20220057384-A1 | SLEEP MODULATION AGENT | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2022-02-24 | — | — | US | disclosed |
| EP-3897599-A1 | SLEEP MODULATION AGENT | Oxford University Innovation Limited (GB) | 2021-10-27 | — | — | EP | disclosed |
| US-20210308189-A1 | METHODS, COMPOSITIONS, AND KITS FOR IMPROVING PANCREATIC BETA CELL VIABILITY AND TREATING DISEASES OR CONDITIONS RELATED TO BETA CELL DESTRUCTION | CITY OF HOPE (US) | 2021-10-07 | — | — | US | disclosed |
| US-10980840-B2 | Methods, compositions, and kits for improving pancreatic beta cell viability and treating diseases or conditions related to beta cell destruction | CITY OF HOPE (US) | 2021-04-20 | — | — | US | disclosed |
| WO-2020128481-A1 | SLEEP MODULATION AGENT | OXFORD UNIVERSTITY INNOVATION LIMITED (GB) | 2020-06-25 | — | — | WO | disclosed |
| US-20190015456-A1 | METHODS, COMPOSITIONS, AND KITS FOR IMPROVING PANCREATIC BETA CELL VIABILITY AND TREATING DISEASES OR CONDITIONS RELATED TO BETA CELL DESTRUCTION | CITY OF HOPE | 2019-01-17 | — | — | US | disclosed |
| US-10022403-B2 | Methods, compositions, and kits for improving pancreatic beta cell viability and treating diseases or conditions related to beta cell destruction | CITY OF HOPE (US) | 2018-07-17 | — | — | US | disclosed |
| US-20160151423-A1 | METHODS, COMPOSITIONS, AND KITS FOR IMPROVING PANCREATIC BETA CELL VIABILITY AND TREATING DISEASES OR CONDITIONS RELATED TO BETA CELL DESTRUCTION | CITY OF HOPE | 2016-06-02 | — | — | US | disclosed |
| US-8748121-B2 | GSH adducts and uses thereof | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748121-B2 | GSH adducts and uses thereof | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748121-B2 | GSH adducts and uses thereof | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-06-10 | — | — | US | disclosed |
| US-20080280319-A1 | GSH adducts and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-11-13 | — | — | US | disclosed |
| US-20080280319-A1 | GSH adducts and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280319-A1 | GSH adducts and uses thereof | GSTA2, GSTA1, GSTM2 | PPARG 2036/4885PPARA 2678/4885TRPA1 2550/4885 |
| US-12527822-B2 | Methods, compositions, and kits for improving pancreatic beta cell viability and treating diseases or conditions related to beta cell destruction | IAPP, PNLIP, RNASE1 | PPARG 2656/4885PPARA 1992/4885TRPA1 3916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.